Biomedical Diagnostics(BMD)

Biomedical Diagnostics (BMD) specializes in innovative in vitro diagnostic solutions for monitoring biotherapies, providing essential tools for healthcare providers to enhance patient management and treatment effectiveness. Biomedical Diagnostics, founded in 1986 in France, develops and sells in vitro diagnostic products tailored to the needs of healthcare institutions. Bertrand de Castelnau leads the company, which has engaged in 19 funding deals to date, with its latest deal occurring on February 24, 2023, raising EUR 28,890. 04.

The company has a current valuation of EUR 15. 622 mn, and total funds raised amount to EUR 0. 029 mn. Theradiag offers a range of CE-marked diagnostic solutions aimed at monitoring biotherapy treatments.

Their flagship product, the LISA TRACKER kits, is designed for clinicians to assess individual patient responses to therapy, supporting effective treatment management. Their clientele consists of hospitals and laboratories primarily in Europe and expanding to international markets, with a focus on oncology and autoimmune disease diagnostics. In 2022, Biomedical Diagnostics reported revenue of EUR 10,973,519. 80 with an EBITDA of EUR -53,779.

60, primarily generated through the sale of diagnostic kits and services under a business-to-business model targeting healthcare institutions and laboratories. The company plans to leverage the recent funding raised in February 2023 to enhance its product portfolio and expand into new markets. Specific upcoming products are in development, with a focus on enhancing offerings for oncology and autoimmune diseases, anticipated to launch within the next year. BMD aims to penetrate additional international markets by 2024, thereby broadening its reach and impact in the diagnostics industry.